GlassScriptPhysician profile
Julie Atkins
NPI 1861192437
$1,136.72
in general payments reported to CMS, 2019-2025
23 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.31 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.73 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $171.33 | 2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $164.20 | 2025 | |
| Genzyme Corporation | $117.58 | 2025 | |
| Pharmacosmos Therapeutics INC. | $71.07 | 2025 | Monoferric |
| Novocure INC. | $61.14 | 2025 | Optune Lua (Novottf-200t) |
| Regeneron Healthcare Solutions, INC. | $59.53 | 2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $55.66 | 2025 | Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $53.83 | 2025 | Fruzaqla |
| Genentech USA, INC. | $51.71 | 2025 | Polivy |
| Puma Biotechnology, INC. | $44.06 | 2025 | |
| Eisai INC. | $33.69 | 2025 | |
| Sobi, INC | $32.66 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.61 | 2025 | |
| Karyopharm Therapeutics INC. | $25.90 | 2025 | Xpovio |
| Celgene Corporation | $23.56 | 2025 | Reblozyl |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.91 | 2025 | Enhertu |
| Emd Serono, INC. | $21.66 | 2025 | |
| Spectrum Pharmaceuticals INC. | $20.59 | 2025 | Rolvedon |
| Dexcom, INC. | $18.31 | 2023 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $17.22 | 2025 | Sylvant |
| Agios Pharmaceuticals, INC. | $15.33 | 2025 | Pyrukynd |
| Abbvie INC. | $14.98 | 2025 | |
| Iovance Biotherapeutics, INC. | $14.19 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Atkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.